Skip to main content
SpringerLink
Log in

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

We have evaluated the use of CD138+ positively selected bone marrow samples to identify a molecular target for minimal residual disease assessment by polymerase chain reaction (PCR) in 25 untreated patients with multiple myeloma. A fraction of each sample was used for CD138+ selection, and the rest served as a reference control. VDJH, DJH, and Kde gene rearrangements were tested for amplification according to the BIOMED-2 Concerted Action. PCR products were directly sequenced in an automated ABI 3130 DNA sequencer using Big-Dye terminators. Within the CD138+ selected group, VDJH rearrangements were detected in all cases (100 %), DJH in 16 (64 %), and Kde in 18 (72 %) cases; whereas in the control samples, VDJH, DJH, and Kde rearrangements were detected in 19 (76 %), 11 (44 %), and 12 (48 %) cases, respectively. After sequencing, 24 (96 %) cases within the CD138+ group had a PCR target for MRD detection compared with 15 (60 %) cases in the control group. We conclude that the use of CD138+ positively selected bone marrow samples increases the applicability of minimal residual disease studies by PCR in patients with multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28:2612–2624

    Article  PubMed  CAS  Google Scholar 

  2. Rajkumar SV, Harousseau JL, Durie B, Anderson KC et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18):4691–4695

    Article  PubMed  CAS  Google Scholar 

  3. Paiva B, Vidriales MB, Cerveró J, Mateo G et al (2008) Multiparameter flow cytometry is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017–40213

    Article  PubMed  CAS  Google Scholar 

  4. Martínez-Sánchez P, Montejano L, Sarasquete ME, García-Sanz R et al (2008) Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-PCR: the prognostic impact of achieving molecular response. Br J Haematol 142:766–774

    Article  PubMed  Google Scholar 

  5. Sarasquete ME, García-Sanz R, González D, Martínez J et al (2005) Minimal residual disease monitoring in multiple myeloma: a comparison between allelic specific real-time oligonucleotide polymerase quantitative and flow cytometry. Haematologica 90:1365–1372

    PubMed  CAS  Google Scholar 

  6. Ladetto M, Pagliano A, Ferrero S, Cavallo F et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084

    Article  PubMed  CAS  Google Scholar 

  7. van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317

    Article  PubMed  Google Scholar 

  8. Martinelli G, Terragna C, Zamagni E, Ronconi S et al (2000) Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18(11):2273–2281

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Phil Mason for checking the English usage and grammar of the manuscript and Alicia Antón for her technical assistance. This work has been partially supported by the grant number PS09/01450 from the Spanish Fondo de Investigaciones Sanitarias. N. Puig was partially supported by a grant from the Sociedad Española de Hematología y Hemoterapia.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain

    Noemí Puig, María E. Sarasquete, Miguel Alcoceba, Ana Balanzategui, María C. Chillón, Elena Sebastián, Luis A. Marín, Marcos González Díaz, Jesús F. San Miguel & Ramón García Sanz

  2. Centro de Investigación del Cáncer (CIC), Universidad de Salamanca, Salamanca, Spain

    María E. Sarasquete, Miguel Alcoceba, María C. Chillón, Luis A. Marín, Marcos González Díaz, Jesús F. San Miguel & Ramón García Sanz

Authors
  1. Noemí Puig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María E. Sarasquete
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Alcoceba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Balanzategui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María C. Chillón
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elena Sebastián
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luis A. Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marcos González Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jesús F. San Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ramón García Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramón García Sanz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Puig, N., Sarasquete, M.E., Alcoceba, M. et al. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Ann Hematol 92, 97–100 (2013). https://doi.org/10.1007/s00277-012-1566-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1566-3

Keywords

Search

Navigation